Skip to content
ETEN
Findshops
Guides

CBD and medical cannabis for migraine: what does the research actually show?

Illustrative photograph accompanying an article on migraine research

Migraine is more than a severe headache. It is a neurological disorder that can involve throbbing pain, nausea, sensitivity to light and sound, and sometimes visual disturbances. Attacks can last hours or even days and seriously disrupt everyday life.

Many people with migraine are therefore interested in cannabis and its active compounds. CBD, or cannabidiol, attracts particular attention because it does not produce the typical THC-related high. But does CBD genuinely relieve migraine, or does that hope mainly rest on people’s experiences?

Research has advanced in recent years. A study published online on 30 December 2025 and in the February 2026 issue of Headache provided placebo-controlled data on vaporized cannabis during acute migraine attacks. Its findings were interesting, while also showing why CBD and THC need to be assessed separately.

What is migraine, and why can it be difficult to treat?

Migraine involves the nervous system and several complex mechanisms, including trigeminal system activity, the brain’s processing of pain signals and signaling molecules such as CGRP.

An attack may cause severe pain on one or both sides of the head, nausea, vomiting and sensitivity to light, sounds and smells. Some people experience an aura before the headache, with symptoms such as flashing lights, visual disturbances or altered sensation.

Evidence-based treatments include triptans, certain pain medicines and newer medicines acting on the CGRP system. Preventive treatments are also used when attacks are frequent.

No medicine works for everyone. Some people get insufficient relief, others experience side effects, and some continue to have attacks despite treatment. That is why researchers continue to investigate options including cannabinoids.

Why are researchers studying cannabis for migraine?

Cannabis contains numerous cannabinoids, of which THC and CBD are the best known. They act differently, but both are studied in relation to the nervous system, pain and inflammatory processes.

The body’s endocannabinoid system helps regulate pain signaling, mood, appetite and several other processes.

Researchers have investigated whether influencing this system might change the activity of migraine-related pathways. The trigeminal system and CGRP-related mechanisms have attracted particular attention.

Laboratory studies provide a biological basis for this hypothesis. However, they do not automatically establish that every cannabis product or cannabinoid is effective against migraine.

Controlled studies in people are needed to answer that question.

A 2026 clinical trial provided stronger evidence

In 2026, the journal Headache published a randomized, double-blind, placebo-controlled trial by University of California San Diego researchers evaluating vaporized cannabis for acute migraine.

420Eesti covered the study’s preliminary results in 2025, before publication of the final journal article.

The trial enrolled and randomized 92 people with migraine. A total of 247 attacks were treated using four preparations:

  • THC-dominant cannabis containing 6% THC;
  • CBD-dominant cannabis containing 11% CBD;
  • a combination containing 6% THC and 11% CBD;
  • placebo cannabis flower.

Participants received the preparations in a randomized order. Researchers assessed outcomes including pain relief, pain freedom and freedom from the most bothersome symptom two hours after treatment.

The THC–CBD combination showed the broadest benefits

The THC–CBD combination produced the most notable findings.

At two hours, pain relief occurred in 67.2% of attacks treated with the combination, compared with 46.6% under placebo.

Pain freedom occurred in 34.5% of attacks treated with the combination, compared with 15.5% under placebo.

Medical research illustration
Medical research illustration. Photo: Edward Jenner / Pexels.

Freedom from the most bothersome migraine symptom occurred in 60.3% of attacks treated with the combination, compared with 34.5% under placebo.

These differences were statistically significant. Some benefits with the combination were also sustained at 24 or 48 hours.

The findings are promising because much earlier research on cannabis and migraine relied on surveys, observational data or smaller, less controlled studies.

What about THC or CBD alone?

The THC-dominant preparation outperformed placebo for pain relief at two hours. However, the findings did not establish superiority for pain freedom or freedom from the most bothersome symptom at that time.

The CBD-dominant preparation did not significantly outperform placebo on the main two-hour outcomes.

This distinction matters.

The study did not establish that CBD has no possible role in migraine. However, it did not support the effectiveness of the CBD-dominant preparation for acute attacks under the conditions tested.

The trial of a THC–CBD combination therefore cannot be used as evidence that ordinary CBD oil relieves migraine.

Can cannabis relieve migraine better than conventional medicines?

This trial cannot answer that question.

It compared cannabis preparations with placebo, rather than migraine medicines such as triptans or medicines acting on the CGRP system.

It therefore cannot establish that cannabis is more effective or works faster than conventional migraine treatments.

Study size is another limitation. Although 92 enrolled participants and 247 treated attacks provide valuable information, they are insufficient for firm conclusions about long-term effectiveness, repeated use or uncommon adverse effects.

Further research should replicate the findings in larger trials and compare standardized cannabinoid preparations with established treatments.

Could CBD prevent migraine?

Treating an acute migraine attack and preventing migraine are different goals.

Acute treatment aims to reduce pain and other symptoms once an attack has begun. Prevention aims to reduce the frequency or severity of attacks over time.

High-quality clinical evidence on CBD as a preventive treatment remains limited.

Some earlier cannabis studies and patient surveys have reported fewer attacks, but often involved THC and CBD together or products whose precise composition was unclear.

Observational data make it difficult to separate treatment effects from placebo responses, lifestyle changes and other factors.

Current evidence is insufficient to recommend CBD as a standard preventive treatment for migraine.

CBD and THC: why their effects are not interchangeable

THC is the main intoxicating cannabinoid in cannabis. It strongly affects CB1 receptors in the brain and can alter pain perception, mood, attention and reaction time.

CBD has a different profile. It does not usually cause the characteristic THC-related high, but it is not biologically inactive.

CBD is being studied in contexts including anxiety, epilepsy, inflammatory processes and pain. A standardized prescription CBD medicine is already used for certain severe epilepsy syndromes.

Our separate review of CBD and anxiety compares clinical findings and their limitations.

That does not make CBD an established treatment for all these conditions.

An important lesson from cannabinoid research is that THC, CBD and other cannabinoids are distinct compounds, rather than stronger or weaker versions of the same ingredient. Their effects can differ, and combinations may produce results that individual compounds do not.

The migraine trial illustrates this distinction.

What risks can cannabinoids carry?

Potential medical value does not mean cannabis use is risk-free.

THC may cause drowsiness, slower reactions, impaired coordination, palpitations and, for some people, anxiety or panic. Vaporization may also irritate the airways.

CBD can cause tiredness, drowsiness, diarrhea and appetite changes. Increased liver enzyme levels have also been reported under certain conditions and at some doses.

Medicine interactions matter. CBD can affect the metabolism of other medicines, while THC-containing preparations can impair attention and judgment.

Products of uncertain composition introduce another problem: their actual THC and CBD content may differ from what the user expects.

No serious adverse events were reported in the migraine trial, but one relatively small study cannot establish long-term safety.

Are CBD or medical cannabis authorized for migraine treatment in Estonia?

CBD itself is not listed as a narcotic or psychotropic substance in Estonia. That does not automatically make every CBD oil, extract or other product lawful.

The legal status of a specific product depends on its origin, composition, THC content, manufacturing process and intended use.

CBD-containing food supplements fall under the European Union’s novel food framework. A low THC content alone does not make a CBD oil a lawful food supplement.

Medical cannabis is regulated separately. Medical use of certain cannabinoid medicines or standardized cannabis preparations is legally possible through a doctor in Estonia, but this does not mean cannabis is routinely available or specifically authorized for migraine.

The CBD prescription medicine Epidyolex has EU authorization as an additional treatment for certain epilepsy syndromes. Migraine is not an approved indication.

Results from a THC–CBD migraine trial abroad do not automatically authorize use of the same preparations in Estonia.

We explain the legal position in greater detail in our 2026 guide to Estonia’s cannabis laws.

What if migraine medicines are not helping?

People with recurring attacks or an inadequate response to treatment should discuss their options with a family doctor or neurologist.

Several treatments with different mechanisms are available, and treatment can sometimes be adjusted or combined. Tracking attack frequency and possible triggers may also help.

Cannabinoid research matters because it could eventually expand evidence-based options for people who do not get enough benefit from existing treatments.

However, experimental cannabinoid treatment should not replace established migraine care or be a reason to stop prescribed treatment without medical advice.

Seek urgent medical attention for a sudden, exceptionally severe headache or a headache accompanied by new neurological symptoms.

Frequently asked questions

Does CBD help with migraine?

CBD’s possible role in migraine is under investigation, but evidence is currently insufficient to consider it an effective migraine treatment. In the placebo-controlled trial published in 2026, the CBD-dominant preparation did not significantly outperform placebo on the main two-hour outcomes.

Can THC relieve migraine?

The THC-dominant preparation provided greater pain relief than placebo in the trial. The THC–CBD combination showed benefits across more key outcomes. Larger and longer-term trials are still needed.

Can CBD oil prevent migraine?

High-quality clinical evidence is insufficient to establish that CBD oil prevents migraine. Findings from an acute-attack trial cannot automatically be applied to long-term preventive use.

Is a THC–CBD combination better than CBD alone?

In the acute migraine trial, the THC–CBD combination outperformed placebo on several outcomes, while the CBD-dominant preparation did not on the main two-hour measures. This does not establish that every product, dose or patient group would have the same results.

Can medical cannabis be prescribed for migraine in Estonia?

Medical cannabis and cannabinoid medicines are regulated in Estonia and may be accessible through a doctor in certain circumstances. Having migraine does not automatically provide entitlement or access to a particular cannabis preparation. Decisions depend on clinical need and the applicable procedures.

Conclusion: cannabis’s potential role in migraine deserves serious research

Research into cannabis and migraine is increasingly informative. The controlled trial published in 2026 is particularly relevant: a THC–CBD combination improved migraine pain and other symptoms more than placebo.

However, the CBD-dominant preparation did not show the same benefit on the main two-hour outcomes. Cannabis compounds need to be studied individually, rather than treating the entire plant as one universal medicine.

A cannabis-friendly perspective can still assess health claims critically. Better research helps establish which conditions cannabinoids may actually help.

For migraine, promising trial findings should be distinguished from treatments whose effectiveness and safety are already well established. Larger independent clinical trials are needed to assess new cannabinoid treatment options.

Sources

Share article
REKLAAMIPIND
Your ad here

Advertising space available.

Get in touch ↗

Lisa kommentaar

Your email address will not be published. Required fields are marked *